As a leading CRO of antibody generation and development, Creative Biolabs offers application-specific antibody development services to global clients. With experienced scientists and advanced technology, we have established a series of high-quality in vitro diagnostic (IVD) antibody development services against biomarkers of different diseases. Here, we introduce our IVD antibody development services for CA19-9 marker.
Cancer Antigen 19-9 (CA19-9)
Cancer antigen 19-9 (CA19-9) is an antigen defined by monoclonal antibody binding to CA19-9, the tumor surface marker Sialyl-Lewis A. It is a tumor marker that is used primarily in the management of pancreatic cancer. CA19-9 can be elevated in many types of gastrointestinal cancer, such as colorectal cancer, esophageal cancer, and hepatocellular carcinoma. Apart from cancer, elevated levels may also occur in pancreatitis, cirrhosis, and diseases of the bile ducts. It can be elevated in people with obstruction of the bile ducts. In patients who lack the Lewis antigen, CA19-9 is not expressed, even in those with large tumors. This is because of a deficiency of a fucosyltransferase enzyme that is needed to produce CA19-9 as well as the Lewis antigen.
CA19-9 Marker of Endometriosis
Endometriosis is a benign gynecological disease that occurs in up to 10% of women of reproductive age (16-50 years old). Although laparoscopy is the gold-standard diagnostic method, ∼66% of women who undergo laparoscopy are found to be free of the disease. Taken together with the potential risks and cost associated with laparoscopy, the development of a noninvasive diagnostic method would have a huge impact on patients' health-related quality-of-life and reduce the number of unnecessary interventions.
CA19-9 exists on the surface of certain cancer cells. Although CA19-9 shaded from the tumor cells, it does not cause cancer, it is only useful to follow the course of cancer. Endometriosis is significantly associated with elevated serum CA19-9 concentrations, and it is increased further in the more advanced stages of the disease. Serum CA19-9 may represent useful biomarkers for the noninvasive diagnosis of endometriosis.
In gynecology, the serum CA19-9 levels are elevated in patients with malignant and benign ovarian tumors. Furthermore, a case of an ovarian chocolate cyst with a markedly elevated serum CA19-9 level has been reported. In addition, it has been reported that serum CA19-9 levels in women with endometriosis are significantly reduced during therapy compared with the basal levels before treatment.
CA19-9 Marker for Pancreatic Cancer
Serum CA 19-9 is the most extensively studied and clinically useful biomarker for pancreatic cancer. The serum level of CA 19-9 can provide essential information with regard to prognosis, overall survival, and response to chemotherapy as well as predict post-operative recurrence. It has been reported that serum CA 19-9 level has a sensitivity and specificity of 79-81% and 82-90% respectively for the diagnosis of pancreatic cancer in symptomatic individuals though it has no role in screening asymptomatic populations. Patients with normal CA 19-9 serum levels (<37 U/ml) have a prolonged median survival (32-36 months) compared to patients with elevated CA 19-9 serum levels (>37 U/ml) (12-15 months), which give the useful prognostic information for clinical operations. It has been reported that the CA 19-9 serum levels smaller than 100 U/ml indicates likely resectable diseases and levels greater than 100 U/ml may suggest unresectable disorders or metastatic diseases. In addition, several research groups have been studying the utility of CA 19-9 for assessing the efficacy of chemotherapy for advanced pancreatic cancer.
IVD Antibody Development Services for CA19-9 Marker
In order to render more precise antibody-based diagnostic tools and assist clinicians in the diagnosis, prognosis, and staging of different diseases and infections, Creative Biolabs provides customized IVD antibody development services targeting the CA19-9 marker to generate high-quality antibodies for diagnostic usage. Besides antibody generation, we also offer antibody conjugation, antibody pairing, and diagnostic immunoassay development services to our clients.
For more detailed information, please feel free to contact us or directly send us an inquiry.
For Research Use Only.
